Janux Therapeutics (JANX) to Release Quarterly Earnings on Tuesday

Janux Therapeutics (NASDAQ:JANX - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $0.59 million for the quarter.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, analysts expect Janux Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Janux Therapeutics Stock Up 2.6 %

Shares of NASDAQ JANX traded up $0.83 during trading on Friday, hitting $32.88. The company had a trading volume of 825,257 shares, compared to its average volume of 847,327. Janux Therapeutics has a fifty-two week low of $22.52 and a fifty-two week high of $71.71. The stock has a fifty day simple moving average of $29.80 and a two-hundred day simple moving average of $42.47. The firm has a market capitalization of $1.95 billion, a price-to-earnings ratio of -28.10 and a beta of 3.27.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 3,334 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $32.15, for a total transaction of $107,188.10. Following the completion of the transaction, the insider now directly owns 82,139 shares in the company, valued at $2,640,768.85. This trade represents a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock in a transaction on Friday, March 7th. The shares were acquired at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares in the company, valued at $314,582,722.74. This represents a 1.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 13,335 shares of company stock worth $454,959 in the last 90 days. Insiders own 29.40% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on JANX shares. Wedbush restated an "outperform" rating and issued a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank lowered their target price on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research note on Friday, February 28th. William Blair reiterated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Finally, HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. One analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and a consensus price target of $95.25.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.